Details:
KAN-101 is a novel immune tolerance therapy, which encompasses an established gluten antigen delivered to the liver and immune system using the company’s proprietary liver-targeting technology.
Lead Product(s): KAN-101
Therapeutic Area: Gastroenterology Product Name: KAN-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
ESO-101 was designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition of mometasone furoate. it has the potential to provide significant clinical benefits to EoE patients.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Gastroenterology Product Name: ESO-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 05, 2023
Details:
ESO-101 (Mometasone Furoate), EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate.
Lead Product(s): Mometasone Furoate
Therapeutic Area: Gastroenterology Product Name: ESO-101
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2022
Details:
This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone.
Lead Product(s): Olamkicept
Therapeutic Area: Gastroenterology Product Name: TJ-301
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: I-Mab Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 09, 2022
Details:
Vibegron was very well tolerated in the study and did not lead to any worsening of IBS symptoms. Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically significant.
Lead Product(s): Vibegron
Therapeutic Area: Gastroenterology Product Name: Gemtesa
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
Proceeds will fund the Phase III program of apraglutide, a potential best-in-class GLP-2 analog, as well as global commercialization and business development activities.
Lead Product(s): Apraglutide
Therapeutic Area: Gastroenterology Product Name: FE203799
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Surveyor Capital
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 15, 2020
Details:
BBT-401, the first-in-class Pellino-1 inhibitor for treatment of ulcerative colitis, is currently in Phase II in the US, and BBT-877, an autotaxin inhibitor to treat various fibrosing interstitial lung diseases including idiopathic pulmonary fibrosis (IPF).
Lead Product(s): BBT-401
Therapeutic Area: Gastroenterology Product Name: BBT-401
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bridge Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 15, 2020